As the industry grapples with increasingly complex modalities and public and investor scrutiny, integrated innovation partners have emerged as critical allies in accelerating programs from concept to clinic. Going beyond transactional services, an integrated partner understands the project holistically, providing therapeutic expertise where there may be gaps and helping to drive the overall success of the program.
In this panel discussion, biotech innovators, pharma R&D leaders, and an integrated CRDMO will unpack what sets high-performing partnerships apart. Using case studies and benchmarks, we’ll discuss how integrated models are best administered to ensure reduced development cycle times, improved IND acceptance rates, and smoother handoffs across the development continuum. We’ll also explore how these outcomes translate into tangible value for early-stage companies seeking funding, partnerships, or acquisition.
Key takeaways:
- Learn how to evaluate development partners and identify strategic fits that drive long-term value
- Examine successful strategies and models to drive collaboration and accelerate timelines
- Discover the benefits of an integrated CRDMO partner and their ability to de-risk early drug development and equip programs with more fundable data packages for investors
- Explore key metrics to determine development partnership model performance and ROI, including impact further along the program pipeline